Gutmann Clemens, Mayr Manuel
King's College London British Heart Foundation Centre, School of Cardiovascular Medicine and Sciences, London, UK.
Platelets. 2022 May 19;33(4):512-519. doi: 10.1080/09537104.2022.2042236. Epub 2022 Mar 9.
Platelets are essential mediators of physiological hemostasis and pathological thrombosis. Currently available tests and markers of platelet activation did not prove successful in guiding treatment decisions for patients with cardiovascular disease, justifying further research into novel markers of platelet reactivity. Platelets contain a variety of microRNAs (miRNAs) and are a major contributor to the extracellular circulating miRNA pool. Levels of platelet-derived miRNAs in the circulation have been associated with different measures of platelet activation as well as antiplatelet therapy and have therefore been implied as potential new markers of platelet reactivity. In contrast to the assessment of platelet reactivity by current platelet function tests, miRNA measurements may enable assessment of platelet reactivity . It remains to be seen however, whether miRNAs may aid clinical diagnostics. Major limitations in the platelet miRNA research field remain the susceptibility to preanalytical variation, non-standardized sample preparation and data normalization that hampers inter-study comparisons. In this review, we provide an overview of the literature on circulating miRNAs as biomarkers of platelet activation, highlighting the underlying biology, the application in patients with cardiovascular disease and antiplatelet therapy and elaborating on technical limitations regarding their quantification in the circulation.
血小板是生理性止血和病理性血栓形成的重要介质。目前可用的血小板活化检测方法和标志物尚未成功用于指导心血管疾病患者的治疗决策,这使得对新型血小板反应性标志物的进一步研究具有合理性。血小板含有多种微小RNA(miRNA),并且是细胞外循环miRNA库的主要贡献者。循环中血小板衍生的miRNA水平与血小板活化的不同指标以及抗血小板治疗相关,因此被认为是血小板反应性的潜在新标志物。与目前通过血小板功能检测评估血小板反应性不同,miRNA检测可能能够评估血小板反应性。然而,miRNA是否有助于临床诊断仍有待观察。血小板miRNA研究领域的主要局限性仍然是易受分析前变异、非标准化样本制备和数据归一化的影响,这妨碍了研究间的比较。在这篇综述中,我们概述了关于循环miRNA作为血小板活化生物标志物的文献,强调了其潜在生物学机制、在心血管疾病患者和抗血小板治疗中的应用,并阐述了其在循环中定量的技术局限性。